Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 003

Drug Profile

TAK 003

Alternative Names: DEN1-DEN2-DEN3-DEN4 vaccine - Takeda Pharmaceuticals USA; Dengue vaccine tetravalent - Takeda Pharmaceuticals USA; DENVax™; Needle-free dengue vaccine; TAK-003; TDV - Takeda Pharmaceuticals USA; Tetravalent dengue vaccine - Takeda Pharmaceuticals USA

Latest Information Update: 12 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centers for Disease Control and Prevention; Inviragen
  • Developer PharmaJet; Takeda Pharmaceuticals USA
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dengue

Most Recent Events

  • 23 Nov 2019 Efficacy and safety data from the phase III TIDES trial in Dengue (In Adolescents, In children, Prevention) released by Takeda
  • 12 Nov 2019 Takeda initiates a phase III trial for Dengue (In adolescents, In adults, Prevention) in USA (SC) (NCT03999996)
  • 07 Nov 2019 Efficacy and safety data from a phase III (TIDES) trial in Dengue (In Adolescents, In children, Prevention) released by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top